Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Status:
Completed
Trial end date:
2017-04-30
Target enrollment:
Participant gender:
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional
treatments having little impact on disease course. Novel approaches are urgently needed to
address inherent resistance to the current therapies and to identify new drugs or
combinations that will have a high chance of success in pancreatic cancer patients. This
proof-of-concept trial is studying the "dynamic" tumor response after the administration of a
short course of gemcitabine and nab-paclitaxel (Abraxane) (a) during a window interval (4
weeks= 1 cycle) before surgery in resectable pancreatic cancer (cohort 1 = 21 patients) and
(b) during at least 8 weeks (2 cycles) in locally advanced or metastatic pancreatic cancer
(cohort 2 = 10 patients).